300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Construction
Oil and Gas
Mobile
Retail
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Enterprise
Transportation
Biotech
Sustainability
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Armenia
Colombia
China
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
New Zealand
Seychelles
Botswana
Paraguay
France
South Africa
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotech VC Funds & Investors in Switzerland (November 2026)

The most active venture capital funds investing in Switzerland Biotech startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Switzerland Biotech startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Foundation for Innovation and Technology (FIT)
VC Fund
52 Switzerland, France, United States Debt Financing, Grant, Seed Health Care, Information Technology, Artificial Intelligence $20k–$2.5M
Zürcher Kantonal Bank
VC Fund
38 Switzerland, Germany, Japan Seed, Series A, Series B Health Care, Biotechnology, Medical Device $1M–$20M
Verve Ventures
VC Fund
20 Switzerland, Germany, France Series A, Seed, Series B Software, Health Care, Biotechnology $1.3M–$45M
BioMedPartners
VC Fund
19 Switzerland, Germany, France Series A, Series B, Series C Biotechnology, Health Care, Medical $5.3M–$75M
Versant Ventures
VC Fund
16 United States, Switzerland, Canada Series A, Series B, Series C Biotechnology, Health Care, Medical $4.7M–$107M
M Ventures
VC Fund
16 United States, United Kingdom, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2.4M–$100M
VI Partners
VC Fund
14 Switzerland, Germany, United States Series A, Series B, Series C Health Care, Biotechnology, Software $3.2M–$100M
Bernina BioInvest
VC Fund
13 Switzerland Seed, Series A, Series B Biotechnology, Health Care, Medical $1.5M–$65M
HTGF (High-Tech Gruenderfonds)
VC Fund
12 Germany, Switzerland, United States Seed, Series A, Venture - Series Unknown Software, Biotechnology, Health Care $680k–$31M
EQT Life Sciences
VC Fund
12 United States, Switzerland, The Netherlands Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $7.3M–$165M
Novartis Venture Fund
VC Fund
11 United States, Switzerland, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $5.1M–$107M
Eclosion SA
VC Fund
11 Switzerland Seed, Series C Biotechnology, Pharmaceutical, Health Care $1.6M–$28M
Schroder Adveq
VC Fund
10 Switzerland, United States, India Series B, Series C, Series A Biotechnology, Health Care, Therapeutics $5M–$100M
SICTIC
VC Fund
10 Switzerland, Germany, Tanzania Seed, Venture - Series Unknown, Pre-Seed Software, Artificial Intelligence, Information Technology $264k–$11M
Sofinnova Partners
VC Fund
10 France, United States, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $7M–$105M
redalpine
VC Fund
9 Germany, Switzerland, United Kingdom Seed, Series A, Series B Artificial Intelligence, Health Care, Biotechnology $1.6M–$125M
Kickfund
VC Fund
9 Switzerland, France, Germany Seed, Pre-Seed, Convertible Note Health Care, Biotechnology, Manufacturing $110k–$5.7M
Kinled Holding
VC Fund
9 United Kingdom, United States, Switzerland Seed, Series A, Venture - Series Unknown Health Care, Biotechnology, Software $594k–$40M
Novo Holdings
VC Fund
8 United States, Denmark, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $9.5M–$135M
GoBeyond
VC Fund
8 Switzerland, Germany, France Venture - Series Unknown, Seed, Series A Software, Information Technology, Health Care $495k–$5.1M
Lichtsteiner Foundation
VC Fund
8 Switzerland Seed, Series A Biotechnology, Health Care, Medical $1.6M–$6.8M
4FOX Ventures
VC Fund
7 Switzerland, United States Series A, Seed, Series B Medical Device, Medical, Health Care $1.8M–$69M
Index Ventures
VC Fund
7 United States, United Kingdom, Germany Series A, Series B, Seed Software, Artificial Intelligence, E-Commerce $1.3M–$102M
Boehringer Ingelheim Venture Fund
VC Fund
7 United States, Germany, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $1.8M–$50M
Omega Funds
VC Fund
6 United States, Switzerland, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $14M–$208M
Swisscom Ventures
VC Fund
6 Switzerland, United States, United Kingdom Series B, Series A, Series C Software, SaaS, Information Technology $2M–$80M
Aglaia BioMedical Ventures
VC Fund
6 The Netherlands, United States, Switzerland Series A, Series B, Seed Biotechnology, Therapeutics, Pharmaceutical $3.7M–$23M
Privilège Ventures
VC Fund
5 Switzerland, Italy, France Seed, Pre-Seed, Series A Health Care, Software, Wearables $667k–$7M
SOSV
VC Fund
5 United States, China, Canada Seed, Convertible Note, Pre-Seed Biotechnology, Health Care, Software $25k–$5M
Pureos Bioventures
VC Fund
5 France, Switzerland, United States Series A, Series B, Series C Biotechnology, Therapeutics, Medical $7.1M–$125M
Founderful
VC Fund
5 Switzerland, United Kingdom, Canada Pre-Seed, Seed, Series A Software, Artificial Intelligence, Information Technology $810k–$24M
Aargauische Kantonalbank
VC Fund
5 Switzerland Series B, Seed, Series A Medical Device, Dental, Medical $1.4M–$3.6M
Pfizer Venture Investments
VC Fund
5 United States, United Kingdom, Switzerland Series B, Series A, Series C Biotechnology, Health Care, Therapeutics $12M–$120M
Broadview Ventures
VC Fund
5 United States, Switzerland, Canada Series A, Seed, Series B Health Care, Biotechnology, Medical Device $1M–$45M
Endeavour Vision
VC Fund
4 United States, Switzerland, France Series C, Series B, Series A Health Care, Medical, Biotechnology $2.1M–$115M
Lakestar
VC Fund
4 United Kingdom, Germany, United States Seed, Series A, Series B Software, Artificial Intelligence, Financial Services $2.2M–$91M
Neomed Management
VC Fund
4 Switzerland, United States, Sweden Series B, Series C, Series A Health Care, Biotechnology, Medical $8.3M–$42M
OrbiMed
VC Fund
4 United States, China, Israel Series B, Series A, Series C Biotechnology, Health Care, Pharmaceutical $8M–$160M
Inkef
VC Fund
4 The Netherlands, United States, Germany Series A, Series B, Seed Biotechnology, Health Care, Medical $3.1M–$86M
Gilde Healthcare
VC Fund
4 United States, The Netherlands, Germany Series B, Series C, Series A Health Care, Biotechnology, Medical $9.5M–$135M
Fongit Seed Invest
VC Fund
4 Switzerland Seed, Series A, Series B Health Care, Medical, Biotechnology $1M–$3.3M
New Enterprise Associates
VC Fund
4 United States, China, India Series A, Series B, Series C Software, Health Care, Biotechnology $5.7M–$100M
Aravis Ventures
VC Fund
4 Switzerland, United States, Belgium Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $4.4M–$80M
b2venture
VC Fund
4 Germany, Switzerland, United States Series A, Seed, Series B Software, Health Care, Information Technology $1.3M–$52M
EVA Basel
VC Fund
4 Switzerland Seed, Series A Biotechnology, Medical Device, Pharmaceutical $1.9M–$3.7M
Polytech Ventures
VC Fund
4 Switzerland, United States, Spain Seed, Series A, Venture - Series Unknown Software, Financial Services, FinTech $500k–$10M
ETH Zurich Foundation
VC Fund
3 Switzerland Pre-Seed, Seed, Grant Medical, Software, 3D Printing $152k–$5.6M
BB Biotech Ventures
VC Fund
3 United States, Switzerland, Italy Series C, Series A, Series B Biotechnology, Health Care, Medical $1.4M–$132M
Bpifrance
VC Fund
3 France, United States, Switzerland Seed, Venture - Series Unknown, Series A Software, Health Care, Biotechnology $752k–$34M
Joyance Partners
VC Fund
3 United States, Germany, United Kingdom Seed, Series A, Pre-Seed Health Care, Biotechnology, Wellness $500k–$18M
Access all 833 VC funds in Switzerland Biotech startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Foundation for Innovation and Technology (FIT)
VC Fund · Lausanne, Vaud, Switzerland · 52 investments in Switzerland Biotech startups, 26 in the past 12 months

The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.

Show more...

Investment focus

  • Industry: Health Care, Information Technology, Artificial Intelligence
  • Stage:Debt Financing, Grant, Seed
  • Geography: Switzerland, France, United States

Investor stats

  • Total investments: 292
  • Round size: Seed $100k–$2.5M; Grant $20k–$125k; Debt Financing $100k–$532k
  • Lead/follow: 94% lead, 6% follow

Portfolio highlights

  • PolaSight — PolaSight delivers a direct, label free visualization of fresh tissue through its automated PolaOne benchtop polarimetric imaging platform. The technology utilizes multi spectral polarimetry to reveal quantitative physical contrast and microstructure details beyond what conventional stained slides show. This non destructive, AI ready optical mapping process provides standardized tissue data right at the bench without requiring freezing or chemical reagents.
  • Swiss Soil — Live biological sensing, adaptive decision-making, and precision inputs that cut waste, respond to real conditions, and build healthier soil.
  • Biodelphis Therapeutics — Swiss biotech developing next-generation protease inhibitors using Antibody-Peptide Inhibitor Conjugates (APIC).
Show all investments...

Zürcher Kantonal Bank
VC Fund · Zürich, Zurich, Switzerland · 38 investments in Switzerland Biotech startups

Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Seed, Series A, Series B
  • Geography: Switzerland, Germany, Japan

Investor stats

  • Total investments: 208
  • Round size: Seed $1M–$6M; Series A $2.1M–$13M; Series B $1.7M–$20M
  • Lead/follow: 13% lead, 87% follow
  • Last fund: Likely still investing — raised $150M in 2024

Portfolio highlights

  • Riverkin — Riverkin builds rugged, low-cost water sensor systems for rivers that measure turbidity and temperature in real time. Our platform turns field data into clear insights and decision making tools.
  • QualySense — QualySense is a Swiss start-up company focused on innovative high-throughput grain, beans and seeds sorting technology. QualySense develops a high-speed multi-tons per hour sorting device, which will change how grains, beans and seeds are processed and valued worldwide by assessing the biochemical quality of grains one by one. The QualySensesorters will enable customers to separate grain batches into different biochemical quality classes and sell the corresponding premium products at higher average prices. Food processors will be able to considerably increase the production value, and produce higher quality products in a non-interrupted process.
  • Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
Show all investments...

Verve Ventures
VC Fund · Zug, Zug, Switzerland · 20 investments in Switzerland Biotech startups, 9 in the past 12 months

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Series A, Seed, Series B
  • Geography: Switzerland, Germany, France

Investor stats

  • Total investments: 308
  • Round size: Seed $1.3M–$12M; Series A $2.1M–$18M; Series B $3.9M–$45M
  • Lead/follow: 14% lead, 86% follow
  • Last fund: Likely still investing — raised $61M in 2022

Portfolio highlights

  • Piomic — Non-invasive treatment with minimal staff supervision to produce a durable structural, functional and cosmetic closure of hard-to-heal wounds.
  • Turn2x — TURN2X decarbonizes the industry by producing Renewable Natural Gas with a unique methanation process.
  • Undecimal Bio — Undecimal Bio operates as a platform biotechnology company that develops targeted delivery mechanisms for small interfering RNA (siRNA) therapeutics. The company utilizes a proprietary platform that combines combinatorial chemistry libraries with transformer-based artificial intelligence to discover molecular conjugates capable of guiding genetic medicines to specified cells outside of the liver. This approach aims to circumvent traditional delivery constraints to expand the reach of RNA therapeutics into a broader range of therapeutic areas and human organs.
Show all investments...

BioMedPartners
VC Fund · Basel, Basel-Stadt, Switzerland · 19 investments in Switzerland Biotech startups

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: Switzerland, Germany, France

Investor stats

  • Total investments: 88
  • Round size: Series A $5.3M–$31M; Series B $5.3M–$75M; Series C $5.3M–$47M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: May invest from a new fund soon — raised $106M in 2018

Portfolio highlights

  • T-CURX — T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care.
  • iDEL Therapeutics — iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism.
  • ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Show all investments...

Versant Ventures
VC Fund · Menlo Park, California, United States · 16 investments in Switzerland Biotech startups

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, Canada

Investor stats

  • Total investments: 339
  • Round size: Series A $4.7M–$68M; Series B $10M–$105M; Series C $12M–$107M
  • Lead/follow: 30% lead, 70% follow
  • Last fund: Likely still investing — raised $5M in 2024

Portfolio highlights

  • Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
  • Gate Bioscience — Gate Bioscience is developing Molecular Gates, a new frontier in protein elimination. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin, inside cells, and prevent them from emerging to cause disease.
  • Dayra Therapeutics — Dayra Therapeutics manufactures peptide based medicines.
Show all investments...

M Ventures
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 16 investments in Switzerland Biotech startups

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 190
  • Round size: Seed $2.4M–$24M; Series A $5.8M–$56M; Series B $13M–$100M
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • Mueon — semiconductor-based systems for AI and hyperscale computing
  • Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
  • iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
Show all investments...

VI Partners
VC Fund · Altendorf, Schwyz, Switzerland · 14 investments in Switzerland Biotech startups

Vi Partners is a venture capital firm backing exceptional founders in healthcare and technology across Switzerland and Europe for over 25 years.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Software
  • Stage:Series A, Series B, Series C
  • Geography: Switzerland, Germany, United States

Investor stats

  • Total investments: 114
  • Round size: Series A $3.2M–$23M; Series B $3.3M–$41M; Series C $7M–$100M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: May invest from a new fund soon — raised $110M in 2020

Portfolio highlights

  • HighLife — HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.
  • Nexthink — Discover what your employees need, see what they experience, know how they feel. Deliver IT that delights.
  • Pay by Shopping (deal united) — paybyshopping.com Domain Name is available to Buy. Grab this great Domain from Daaz. Daaz has the lowest transaction fees in the industry. See our list of GTLD's,CCTLD's, New GTLD's,3N's, 6N's, 3L's, 6L's etc.
Show all investments...

Bernina BioInvest
VC Fund · Zug, Zug, Switzerland · 13 investments in Switzerland Biotech startups

Bernina BioInvest is an investment Firm.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: Switzerland

Investor stats

  • Total investments: 16
  • Round size: Seed $1.5M–$20M; Series A $15M–$65M
  • Lead/follow: 25% lead, 75% follow

Portfolio highlights

  • Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
  • HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
  • Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Show all investments...

HTGF (High-Tech Gruenderfonds)
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 12 investments in Switzerland Biotech startups

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in various sectors.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Seed, Series A, Venture - Series Unknown
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 851
  • Round size: Seed $680k–$6.5M; Series A $3M–$31M; Venture - Series Unknown $911k–$12M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: Likely still investing — raised $515M in 2022

Portfolio highlights

  • Extoll — EXTOLL, a leader in high-speed, ultra-low power SerDes and Chiplet connectivity, offers semiconductor IP with the smallest footprints and highest PPA. Serving global ASIC, SoC, and Chiplet markets, our portfolio includes tailored NoC (Network-on-Chip) and Die-to-Die solutions. EXTOLL drives innovation, enabling successful migration into the Chiplet Age.
  • Selfapy — Selfapy offers a therapy support tool that helps recognize negative patterns of thought and train new behavior. Selfapy is your guided, self-help online course against depression with a personal psychologist as a companion.
  • BlueID GmbH — Smart locks for professionals. BlueID delivers flexible, secure and convenient smart locks for all doors in and around your office.
Show all investments...

EQT Life Sciences
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 12 investments in Switzerland Biotech startups

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, The Netherlands

Investor stats

  • Total investments: 190
  • Round size: Series A $7.3M–$78M; Series B $11M–$114M; Series C $12M–$165M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: Likely still investing — raised $282M in 2023

Portfolio highlights

  • Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
  • ActoGeniX — ActoGeniX is a biopharmaceutical company focused on the development and commercialization of a range of biological drugs. ActoGeniX was founded by Bernard Coulie and Mark Vaeck in 2006 and is based in Zwijnaarde, Belgium.
  • Vaderis Therapeutics — Vaderis Therapeutics is a biotechnology company in the clinical stages that specializes in the treatment of uncommon and orphan diseases.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Novartis Venture Fund
VC Fund · Basel, Basel-Stadt, Switzerland · 11 investments in Switzerland Biotech startups

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, United Kingdom

Investor stats

  • Total investments: 247
  • Round size: Series A $5.1M–$81M; Series B $11M–$107M; Series C $9M–$75M
  • Lead/follow: 26% lead, 74% follow
  • Last fund: May invest from a new fund soon — raised $200M in 2009

Portfolio highlights

  • Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
  • Visiogen — Visiogen, Inc. is an ophthalmic medical device company specializing in the development of new vision alternatives for patients with cataracts, with and without presbyopia. As part of this mission, Visiogen created the Synchrony dual optic accommodating *intraocular lens (IOL)* for use in the surgical treatment of these conditions.The device isdesigned to provide patients with near, intermediate and distance vision in a seamless continuum without the need for glasses or contact lenses. To eliminate lens handling during surgery, the Synchrony dual optic IOL is provided in a pre-loaded injector. This patented technology has been approved in Europe with a CE Mark designation and is currently undergoing clinical trials in the United States.
  • Rein Therapeutics — Harnessing fibrosis, unleashing life
Show all investments...

Eclosion SA
VC Fund · Geneva, Geneve, Switzerland · 11 investments in Switzerland Biotech startups

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up can reasonably attract risk capital. Eclosion helps you to cross the bridge to convert your innovation into a realistic venture and to enter into its growth phase.

Show more...

Investment focus

  • Industry: Biotechnology, Pharmaceutical, Health Care
  • Stage:Seed, Series C
  • Geography: Switzerland

Investor stats

  • Total investments: 16
  • Round size: Seed $1.6M–$3.3M; Series C $20M–$28M
  • Lead/follow: 56% lead, 44% follow

Portfolio highlights

  • KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
  • Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
  • MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Show all investments...

Schroder Adveq
VC Fund · Zürich, Zurich, Switzerland · 10 investments in Switzerland Biotech startups

Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series C, Series A
  • Geography: Switzerland, United States, India

Investor stats

  • Total investments: 36
  • Round size: Series A $5M–$22M; Series B $11M–$73M; Series C $15M–$100M
  • Lead/follow: 11% lead, 89% follow
  • Last fund: May invest from a new fund soon — raised $113M in 2020

Portfolio highlights

  • Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
  • Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able to do in India yet. The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery. Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision to name a few) and be it disposable, toric, colored, or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
  • Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
Show all investments...

SICTIC
VC Fund · Zürich, Zurich, Switzerland · 10 investments in Switzerland Biotech startups

SICTIC is the leading angel investor network in Switzerland with the largest Swiss seed-stage startup dealflow.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Seed, Venture - Series Unknown, Pre-Seed
  • Geography: Switzerland, Germany, Tanzania

Investor stats

  • Total investments: 301
  • Round size: Seed $504k–$3.7M; Pre-Seed $264k–$2.7M; Venture - Series Unknown $1.2M–$11M
  • Lead/follow: 27% lead, 73% follow

Portfolio highlights

  • hypt — hypt is a Swiss based SaaS marketing solution that empowers companies to digitalize word-of-mouth. By using our word-of-mouth manager companies are able to activate 40% of their customers to send out a personal recommendation to their peers increasing sales through word-of-mouth by 4 times. Our solution empowers our ICP customers in the finance andinsurance segments to strategically use and optimize the most authentic and cost effective advertising channel – word-of-mouth – and makes it an accessible asset of every marketing mix.
  • Carewell — Carewell is influencing the way people work in healthcare by providing flexible digital solutions tailored to their specific needs.
  • Prevision Medicine — Prevision Medicine AG is a oncology company that provides cancer therapy, tests living cancer cells, and deliver clinical insights.
Show all investments...

Sofinnova Partners
VC Fund · Paris, Ile-de-France, France · 10 investments in Switzerland Biotech startups

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: France, United States, United Kingdom

Investor stats

  • Total investments: 360
  • Round size: Series A $7M–$70M; Series B $10M–$105M; Series C $12M–$100M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: Likely actively investing — fresh fund, raised $755M in 2025

Portfolio highlights

  • Odoo — From ERP to CRM, eCommerce and CMS. Download Odoo or use it in the cloud. Grow Your Business.
  • IMIO — Improve efficiency across the crop nutrient cycle. IMIO natural microbial products reliably increase nutrient availability and reduce tillage.
  • DMC Biotechnologies — Transforming How the World Makes Chemicals
Show all investments...

redalpine
VC Fund · Zürich, Zurich, Switzerland · 9 investments in Switzerland Biotech startups, 18 in the past 12 months

redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.

Show more...

Investment focus

  • Industry: Artificial Intelligence, Health Care, Biotechnology
  • Stage:Seed, Series A, Series B
  • Geography: Germany, Switzerland, United Kingdom

Investor stats

  • Total investments: 207
  • Round size: Seed $1.6M–$13M; Series A $2.8M–$33M; Series B $16M–$125M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: Likely still investing — raised $200M in 2024

Portfolio highlights

  • calliora — Calliora develops an artificial intelligence platform designed to integrate hospital clinical documentation and coding systems to identify billing errors before invoices are sent to health insurers
  • Basecamp Research — Novel proteins from nature. We sample the most extreme and exciting places on the planet to build the world's largest knowledge graph of natural biodiversity.
  • Enact Intelligence — Enact Intelligence builds underlying technology for general-purpose robots, reimagining the entire robotic stack from the ground up to solve the ultimate bottleneck in robotics: dexterity. Rather than relying primarily on vision models, Enact builds proprietary actuators that measure force directly inside the joints. This creates a human-like "nervous system" and muscle feedback loop, allowing robots to efficiently learn and robustly execute highly precise, contact-rich physical tasks across industrial, retail, and manufacturing environments.
Show all investments...

Kickfund
VC Fund · Basel, Basel-Stadt, Switzerland · 9 investments in Switzerland Biotech startups, 11 in the past 12 months

Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Manufacturing
  • Stage:Seed, Pre-Seed, Convertible Note
  • Geography: Switzerland, France, Germany

Investor stats

  • Total investments: 51
  • Round size: Seed $1.1M–$5.7M; Pre-Seed $335k–$4M; Convertible Note $110k–$118k
  • Lead/follow: 16% lead, 84% follow
  • Last fund: Likely still investing — raised $80M in 2023

Portfolio highlights

  • Bewelab SA — Bewe is a mobile game designed to reduce cravings, using neuroscience to automatically retrain your brain and effortlessly reclaim your health.
  • Immitra Bio — Developing scalable in-vivo genomic medicine for blood disorders
  • Helix Robotics — We are building the first commercial soft manipulator
Show all investments...

Kinled Holding
VC Fund · New York, New York, United States · 9 investments in Switzerland Biotech startups

Kinled was founded in 1980 to retain the investment assets of the Aisher family. In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists. Since then, Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Software
  • Stage:Seed, Series A, Venture - Series Unknown
  • Geography: United Kingdom, United States, Switzerland

Investor stats

  • Total investments: 144
  • Round size: Seed $594k–$14M; Series A $1.7M–$40M; Venture - Series Unknown $1.6M–$13M
  • Lead/follow: 3% lead, 97% follow

Portfolio highlights

  • Esper — Esper is the first cloud-based platform to help governments proactively manage public policy with better data and transparency.
  • Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
  • TAG Therapeutics — TAG Therapeutics develops precision medicine approaches for telomere pathologies and aging-related diseases, such as Idiopathic Pulmonary Fibrosis and Short Telomere Syndromes
Show all investments...

Novo Holdings
VC Fund · Hellerup, Hovedstaden, Denmark · 8 investments in Switzerland Biotech startups

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 415
  • Round size: Series A $9.5M–$133M; Series B $15M–$135M; Series C $35M–$118M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: May invest from a new fund soon — raised $165M in 2018

Portfolio highlights

  • Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
  • SCHOTT Poonawalla — SCHOTT Poonawalla is a manufacturer of pharmaceutical containers, made of neutral glass tubing. The company provides parenteral packaging systems crafted from tubular glass, serving the pharmaceutical industry with a broad range of products including vials, pre-fillable syringes, ampoules, and cartridges.
  • Vantia Therapeutics — Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and representbillion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners.
Show all investments...

GoBeyond
VC Fund · Zürich, Zurich, Switzerland · 8 investments in Switzerland Biotech startups

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders. Its clients are individuals, family offices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Venture - Series Unknown, Seed, Series A
  • Geography: Switzerland, Germany, France

Investor stats

  • Total investments: 206
  • Round size: Seed $495k–$5M; Series A $1.1M–$4.5M; Venture - Series Unknown $681k–$5.1M
  • Lead/follow: 5% lead, 95% follow

Portfolio highlights

  • LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
  • Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.
  • Sensima Technology — Sensima Technology designs and supplies magnetic sensors for angle measurement and 3D magnetic field sensing. The company’s product portfolio includes MagAlpha, which instantaneously detects and delivers the angle value in digital format. Sensima Technology is based in Gland, Switzerland.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Lichtsteiner Foundation
VC Fund · Berne, Bern, Switzerland · 8 investments in Switzerland Biotech startups

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: Switzerland

Investor stats

  • Total investments: 11
  • Round size: Seed $1.6M–$6.8M
  • Lead/follow: 9% lead, 91% follow

Portfolio highlights

  • Hemostod — Developing universal platelets and next-generation diagnostics
  • DigeHealth — DigeHealth is a Swiss company building a wearable that continuously listens to your gut, turning bowel sounds and body signals into a daily picture of your gut health.
  • Allegria Therapeutics — Allegria Therapeutics is a Swiss biotech company targeting mast cells to redefine the treatment of allergic and inflammatory diseases.
Show all investments...

4FOX Ventures
VC Fund · Luxembourg, Luxembourg, Luxembourg · 7 investments in Switzerland Biotech startups

4FO Ventures

Show more...

Investment focus

  • Industry: Medical Device, Medical, Health Care
  • Stage:Series A, Seed, Series B
  • Geography: Switzerland, United States

Investor stats

  • Total investments: 23
  • Round size: Seed $1.8M–$3.3M; Series A $1.8M–$11M; Series B $5.5M–$69M
  • Lead/follow: 52% lead, 48% follow

Portfolio highlights

  • Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
  • Ecorobotix — Discover how Ecorobotix is revolutionizing precision agriculture with AI-driven field sprayers. Cut costs, boost yields, and farm smarter with precision ag technology.
  • Neo Medical — Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.
Show all investments...

Index Ventures
VC Fund · San Francisco, California, United States · 7 investments in Switzerland Biotech startups

Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, E-Commerce
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Germany

Investor stats

  • Total investments: 1635
  • Round size: Seed $1.3M–$16M; Series A $5M–$35M; Series B $12M–$102M
  • Lead/follow: 43% lead, 57% follow
  • Last fund: Likely actively investing — fresh fund, raised $400M in 2026

Portfolio highlights

  • PanGenetics — PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases.PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employsa lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients
  • Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.
  • Milestone Systems — See and know more with video technology. Milestone offers award-winning XProtect video management software, Arcules VSaaS, and BriefCam analytics.
Show all investments...

Boehringer Ingelheim Venture Fund
VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 7 investments in Switzerland Biotech startups, 6 in the past 12 months

Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Germany, Switzerland

Investor stats

  • Total investments: 108
  • Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
  • Lead/follow: 48% lead, 52% follow
  • Last fund: May invest from a new fund soon — raised $250M in 2018

Portfolio highlights

  • Tacalyx — Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms.
  • smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
  • Cloverleaf Bio — Cloverleaf Bio | Developing a new class of RNA therapeutics to revolutionize cancer therapy.
Show all investments...

Omega Funds
VC Fund · Boston, Massachusetts, United States · 6 investments in Switzerland Biotech startups

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Switzerland, United Kingdom

Investor stats

  • Total investments: 172
  • Round size: Series A $16M–$200M; Series B $38M–$165M; Series C $14M–$208M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — raised $470M in 2023

Portfolio highlights

  • Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
  • Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
  • Anaconda BioMed — Anaconda Biomed, headquartered in Barcelona, Spain, is among the world's most innovative early stage medical technology companies. The company was founded by Dr. Ofir Arad and Dr. Marc Ribó in 2015, and is developing the ANCD BRAIN™, a novel 3rd Generation Stented Aspiration Thrombectomy System for the treatment of Acute Ischemic Stroke (AIS).
Show all investments...

Swisscom Ventures
VC Fund · Zurich, Zurich, Switzerland · 6 investments in Switzerland Biotech startups

Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007. Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technical expertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services. Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.

Show more...

Investment focus

  • Industry: Software, SaaS, Information Technology
  • Stage:Series B, Series A, Series C
  • Geography: Switzerland, United States, United Kingdom

Investor stats

  • Total investments: 159
  • Round size: Series A $2M–$22M; Series B $2M–$60M; Series C $8.6M–$80M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — raised $300M in 2022

Portfolio highlights

  • Apono — Apono makes permission management to applications, infrastructure, and data repositories simple, secure and compliant.
  • CDDS — The CDDS interceptor is an autonomous, kinetic counter drone designed to neutralize Group 1 and Group 2 Unmanned Aerial System (UAS) threats with speed and precision.
  • Aylight — Aylight develops semiconductor laser and photonics platforms designed to improve optical connectivity in AI datacenters and related infrastructure. The company focuses on frequency modulated comb laser technology that generates multiple stable wavelengths from a single InP-based laser cavity. Its architecture produces an equidistant, RF-lockedwavelength grid that aligns with dense wavelength-division multiplexing requirements and reduces control complexity and power consumption. Aylight targets use cases in AI datacenter interconnects, quantum computing hardware, precision metrology, and communication equipment. Its products aim to integrate with terabit optical links and wavelength-division multiplexing systems while remaining compatible with existing fabrication processes.
Show all investments...

Aglaia BioMedical Ventures
VC Fund · Bilthoven, Utrecht, The Netherlands · 6 investments in Switzerland Biotech startups

Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since thenumber of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia's focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.

Show more...

Investment focus

  • Industry: Biotechnology, Therapeutics, Pharmaceutical
  • Stage:Series A, Series B, Seed
  • Geography: The Netherlands, United States, Switzerland

Investor stats

  • Total investments: 14
  • Round size: Seed $3.7M–$3.7M; Series A $5.5M–$17M; Series B $21M–$23M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: May invest from a new fund soon — raised $65M in 2014

Portfolio highlights

  • Inthera Bioscience — Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.
  • InteRNA Technologies — A Dutch clinical-stage biotech company InteRNA Technologies is a Dutch clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading microRNA (miRNA) discovery and functional validation technology platform and enabled with a 3rd-generation drug delivery
  • Sapreme Technologies — Enabling endosomal escape
Show all investments...

Privilège Ventures
VC Fund · Zürich, Zurich, Switzerland · 5 investments in Switzerland Biotech startups

Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary over five decades of combined investment experience Where Entrepreneurs Thrive Rooted in reality, reaching for the extraordinary Authentic, dedicated, disciplined, and goal-oriented, our team drives meaningful and lasting success About Team

Show more...

Investment focus

  • Industry: Health Care, Software, Wearables
  • Stage:Seed, Pre-Seed, Series A
  • Geography: Switzerland, Italy, France

Investor stats

  • Total investments: 24
  • Round size: Seed $1M–$5.9M; Pre-Seed $667k–$1.6M; Series A $4.1M–$7M
  • Lead/follow: 54% lead, 46% follow
  • Last fund: Likely still investing — raised $21M in 2022

Portfolio highlights

  • Xsensio — Xsensio develops the unique Lab-on-Skin™​ sensing platform to sense in real-time biochemical information at the surface of the skin, providing unprecedented real-time information about our health and wellness, in a simple and non-invasive way.The Xsensio Lab-on-Skin™ sensing chip relies on a unique, highly-miniaturized sensing platform developedat the Nanolab of the Swiss Federal Institute of Technology. By leveraging semiconductor properties, our sensing platform unleashes a whole new set of possibilities in continuous health monitoring.
  • ENANTIOS — ENANTIOS specializes in creating benchtop analytical instruments that provide industries, research institutions, and academic facilities.
  • Develop Players — Supporto clinico per ADHD e DSA online. Aiutiamo adulti, bambini e ragazzi con screening, potenziamento e percorsi psicologici personalizzati.
Show all investments...

SOSV
VC Fund · Princeton, New Jersey, United States · 5 investments in Switzerland Biotech startups

SOSV offers pre-seed capital and follow-on financial support to startups focusing on deep technology and scientific innovation. Founders utilize purpose-built laboratory facilities and engineering spaces to accelerate product development and testing. The firm facilitates connections between entrepreneurs and a network of investors through structured matchmaking events and technology summits.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Convertible Note, Pre-Seed
  • Geography: United States, China, Canada

Investor stats

  • Total investments: 3821
  • Round size: Seed $125k–$5M; Pre-Seed $25k–$1.5M; Convertible Note $50k–$3.6M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: Likely still investing — raised $306M in 2023

Portfolio highlights

  • Halla — Halla Intelligence is a digital solution that leverages over 100 billion shopper and product data points to recommend and promote what grocery items.
  • Verdex Technologies — Verdex Technologies is an advanced materials platform technology that uses nanofibers to disrupt industries. Verdex doesn't just compete, it innovates and disrupts.
  • Samphire Neuroscience — Samphire Neuroscience builds clinically validated neurotechnology to support women across their lives. Our wearable devices, Nettle™ and Lutea™, are built on the same underlying brain-stimulation technology, targeting neural pathways involved in pain, mood, stress, and sleep regulation. - Lutea™ is available globally as a wellness device. Itstimulates the same regions of the brain to support stress regulation, sleep, and recovery - key drivers of readiness and long-term performance - allowing athletes and teams to move beyond wellbeing education alone to practical, evidence-based intervention. - Nettle™ is a CE-marked (EU and UK regulated), drug- and hormone-free device that has been clinically shown to improve pain, mood, functionality, and the ability to train during the menstrual cycle, with measurable benefits after one month of use - supporting athletes to maintain training intensity and movement quality during their period. - The Samphire App is the platform controlling all Samphire hardware products with the use of CycleSync™ AI technology: the only one of its kind to support personalized neurotechnology use for women.
Show all investments...

Pureos Bioventures
VC Fund · Küsnacht, Zurich, Switzerland · 5 investments in Switzerland Biotech startups

Venture capital for companies developing innovative therapeutics.

Show more...

Investment focus

  • Industry: Biotechnology, Therapeutics, Medical
  • Stage:Series A, Series B, Series C
  • Geography: France, Switzerland, United States

Investor stats

  • Total investments: 37
  • Round size: Series A $12M–$123M; Series B $7.1M–$100M; Series C $22M–$125M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: May invest from a new fund soon — raised $205M in 2020

Portfolio highlights

  • AnaCardio — AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
  • NovaGo Therapeutics — NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics targeting cerebral stroke and spinal cord injury to stimulate nerve repair and regeneration. A strategic partnership with Neurimmune provides access to a unique class of human-derived antibodies with exceptional therapeutic propertiesgenerated through their Reverse Translational Medicine™ (RTM™) technology platform.
  • PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Founderful
VC Fund · Zürich, Zurich, Switzerland · 5 investments in Switzerland Biotech startups, 10 in the past 12 months

Founderful is Switzerland’s leading pre-seed fund. Founderful is the first, fast, and founder-friendly, backing Switzerland's best tech entrepreneurs to become global market leaders. Founded in 2019 and is located in Zurich, Zurich.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Pre-Seed, Seed, Series A
  • Geography: Switzerland, United Kingdom, Canada

Investor stats

  • Total investments: 112
  • Round size: Seed $1.5M–$14M; Pre-Seed $810k–$4.3M; Series A $3M–$24M
  • Lead/follow: 55% lead, 45% follow
  • Last fund: Likely still investing — raised $143M in 2024

Portfolio highlights

  • UniSieve — UniSieve is a cleantech company that provides molecular separation membrane solutions for a wide range of applications. Its platform technology enables a unique combination of various molecular sieves and polymeric membranes, yielding reliable separation solutions. The company was founded in 2018 and is headquartered in Zurich, Switzerland.
  • Fusionality — Fusionality is a Swiss fusion-technology company focused on measurement, control, and data systems for fusion devices.They combine expertise in fusion physics, control engineering, AI/ML, simulation, diagnostics, and real-time software.Their goal is to help fusion companies and research labs operate devices more efficiently and accelerate thedevelopment of commercial fusion energy.
  • Exclaim Robotics — Autonomous mobile robots for the AI data center.
Show all investments...

Aargauische Kantonalbank
VC Fund · Aarau, Aargau, Switzerland · 5 investments in Switzerland Biotech startups

Aargauische Kantonalbank (AKB) is a classical universal bank for private and corporate clients and institutional investors. They offer comprehensive services in all areas of banking. Their strengths include the needs-based, personalized and comprehensive advice and a comprehensive and competent care. The AKB has 31 offices in the canton of Aargau and the adjacent area Solothurn Olten-Gösgen-Gäu. Their company has about 790 employees and about 79 students. They serve approximately 230,000 customers. The AKB has been awarded by the rating agency Standard & Poor's AA + rating.

Show more...

Investment focus

  • Industry: Medical Device, Dental, Medical
  • Stage:Series B, Seed, Series A
  • Geography: Switzerland

Investor stats

  • Total investments: 13
  • Round size: Seed $1.5M–$3.6M; Series B $1.4M–$2.3M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Aliunid — Aliunid is a cleantech startup that records, optimizes, and controls energy flows using real-time data.
  • Mesh — MESH is automating rebar fabrication and construction processes using robotics and software. Our mission is to bring modern robotics to rebar industry.
  • Pearltec AG — Headquartered in Schlieren / Zurich, Pearltec AG develops, produces and delivers solutions for the optimal storage, fixation and positioning of patients. Their products are based on unique, patented technology developed in collaboration with ETH Zurich and renowned university hospitals.They have set theirselves the goal to use the technologycompetence of Pearltec AG for the benefit of humans, animals and industry and to create added value for their customers by excellent quality and convincing application advantages.Pearltec AG is certified according to ISO standard 13485. This certification certifies that their quality management system for the development and manufacture of medical devices meets the highest international standards.
Show all investments...

Pfizer Venture Investments
VC Fund · New York, New York, United States · 5 investments in Switzerland Biotech startups

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of its industry.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 189
  • Round size: Series A $12M–$100M; Series B $20M–$120M; Series C $15M–$102M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: May invest from a new fund soon — raised $600M in 2018

Portfolio highlights

  • Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
  • Flexion Therapeutics — Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.
  • TwoStep Therapeutics — TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors.
Show all investments...

Broadview Ventures
VC Fund · Boston, Massachusetts, United States · 5 investments in Switzerland Biotech startups

Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures. The Foundation Leducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support. With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series A, Seed, Series B
  • Geography: United States, Switzerland, Canada

Investor stats

  • Total investments: 86
  • Round size: Seed $1M–$18M; Series A $1M–$20M; Series B $2.5M–$45M
  • Lead/follow: 27% lead, 73% follow

Portfolio highlights

  • Adient Medical — Medical Devices that Automatically Vanish - Adient Medical is leading the development of an absorbable vascular filter for the prevention of pulmonary embolism.
  • HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
  • Viridian Therapeutics (Formerly MiRagen Therapeutics) — Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions
Show all investments...

Endeavour Vision
VC Fund · Geneva, Geneve, Switzerland · 4 investments in Switzerland Biotech startups

Endeavour Vision is an investment advisory firm focused on transformative healthcare technologies.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Series C, Series B, Series A
  • Geography: United States, Switzerland, France

Investor stats

  • Total investments: 77
  • Round size: Series A $2.1M–$30M; Series B $7M–$48M; Series C $12M–$115M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: May invest from a new fund soon — raised $375M in 2021

Portfolio highlights

  • Nalu Medical — Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
  • Venture Med Group — VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients.Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly costeffective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.
  • Kestra Medical Technologies, Inc. — Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects patients with diagnostic and therapeutic technologies that are intuitive, and mobile. They provide intuitive medical technologies to protect and support at-risk patients.
Show all investments...

Lakestar
VC Fund · Zürich, Zurich, Switzerland · 4 investments in Switzerland Biotech startups, 26 in the past 12 months

Lakestar invests in founders and technologies shaping Europe's future, helping build resilience, sovereignty, and long-term growth in a changing world.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Financial Services
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, Germany, United States

Investor stats

  • Total investments: 258
  • Round size: Seed $2.2M–$19M; Series A $6.7M–$65M; Series B $17M–$91M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: Likely actively investing — fresh fund, raised $300M in 2026

Portfolio highlights

  • Ravical — Ravical equips professional services firms with AI agents that collaborate and scale, unlocking practical value today and future growth tomorrow.
  • Modulate — Modulate uses revolutionary machine learning to proactively detect and escalate toxic behavior in your game. ToxMod becomes an expert in your code of conduct and empowers your moderators to make the right decisions to protect your community from the worst behavior happening in voice chat in real time.
  • Ares Intelligence — Ares Intelligence conducts automated internal interviews across a company's workforce to analyze operational inefficiencies and identify where the business can integrate artificial intelligence effectively.
Show all investments...

Neomed Management
VC Fund · Oslo, Oslo, Norway · 4 investments in Switzerland Biotech startups

NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date. NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that address substantial market opportunities in the pharmaceutical, medical device and diagnostics industries. NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America. From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies. NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series B, Series C, Series A
  • Geography: Switzerland, United States, Sweden

Investor stats

  • Total investments: 46
  • Round size: Series A $8.3M–$37M; Series B $21M–$42M; Series C $9.2M–$41M
  • Lead/follow: 13% lead, 87% follow
  • Last fund: May invest from a new fund soon — raised $51M in 2015

Portfolio highlights

  • Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
  • Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
  • JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.
Show all investments...

OrbiMed
VC Fund · New York, New York, United States · 4 investments in Switzerland Biotech startups

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series B, Series A, Series C
  • Geography: United States, China, Israel

Investor stats

  • Total investments: 790
  • Round size: Series A $8M–$116M; Series B $18M–$148M; Series C $18M–$160M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: Likely actively investing — fresh fund, raised $192M in 2026

Portfolio highlights

  • CoGenesys — CoGenesys is a biopharmaceutical company focused on the development of peptide- and protein-based medicines. The company develops peptide and protein-based medicines for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.
  • InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
  • Bonovo Orthopedics —
Show all investments...

Inkef
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 4 investments in Switzerland Biotech startups

SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Seed
  • Geography: The Netherlands, United States, Germany

Investor stats

  • Total investments: 93
  • Round size: Seed $3.1M–$24M; Series A $3.4M–$42M; Series B $9M–$86M
  • Lead/follow: 49% lead, 51% follow
  • Last fund: May invest from a new fund soon — raised $562M in 2016

Portfolio highlights

  • Silverflow — Silverflow offers global payment technology to power financial institutions.
  • Provable Markets — A comprehensive suite of trading & trade management solutions for the front, middle, and back office
  • Quantum Motion — Quantum Motion Technologies is building a universal quantum computer in Silicon, using CMOS compatible processes.
Show all investments...

Gilde Healthcare
VC Fund · Utrecht, Utrecht, The Netherlands · 4 investments in Switzerland Biotech startups, 6 in the past 12 months

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcare services. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series B, Series C, Series A
  • Geography: United States, The Netherlands, Germany

Investor stats

  • Total investments: 131
  • Round size: Series A $9.5M–$62M; Series B $14M–$135M; Series C $21M–$80M
  • Lead/follow: 38% lead, 62% follow
  • Last fund: Likely actively investing — fresh fund, raised $296M in 2026

Portfolio highlights

  • Big Health — Our mission is to help millions back to good mental health. Our digital therapeutics are safe and effective non-drug alternatives for mental health.
  • GT Medical Technologies — GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes.
  • Endovascular Engineering — Endovascular Engineering is a medical technology company focused on developing and deploying advanced clot removal solutions for the treatment of venous thromboembolism. It specializes in thrombectomy technologies designed to improve clinical outcomes and procedural efficiency in minimally invasive vascular interventions. The company’s flagshipinnovation is the Hēlo™ Thrombectomy System, a catheter-based device that uses a combination of mechanical agitation and physician-controlled aspiration to remove blood clots. Its technology emphasizes features such as a self-expanding funnel design and dual-action functionality to enhance clot engagement and navigation through complex anatomies. Endovascular Engineering primarily serves healthcare providers, including interventional cardiologists and radiologists, supporting the treatment of conditions such as pulmonary embolism and deep vein thrombosis.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Fongit Seed Invest
VC Fund · Plan-les-ouates, Geneve, Switzerland · 4 investments in Switzerland Biotech startups

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Show more...

Investment focus

  • Industry: Health Care, Medical, Biotechnology
  • Stage:Seed, Series A, Series B
  • Geography: Switzerland

Investor stats

  • Total investments: 9
  • Round size: Seed $1M–$1.4M; Series A $2.3M–$3.3M
  • Lead/follow: 56% lead, 44% follow

Portfolio highlights

  • EBAMed — EBAMed builds CardioKit: live ultrasound that follows the heart during radiotherapy and gates the beam, whether the heart is the target or the organ to protect.
  • Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
  • Annaida Technologies — Empowering fertility providers and researchers with AI-driven metabolomic platforms. Non-invasive, real-time insights at the microscale for personalized medical treatments.
Show all investments...

New Enterprise Associates
VC Fund · Menlo Park, California, United States · 4 investments in Switzerland Biotech startups

Foundational partners to ambitious founders at every stage of company-building.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Series A, Series B, Series C
  • Geography: United States, China, India

Investor stats

  • Total investments: 2171
  • Round size: Series A $5.7M–$53M; Series B $10M–$85M; Series C $15M–$100M
  • Lead/follow: 39% lead, 61% follow
  • Last fund: Likely still investing — raised $468M in 2024

Portfolio highlights

  • Uhana — Modernize your RAN to be open and programmable, built with a rich ecosystem of partners. Learn about VMware RAN Intelligent Controller (RIC).
  • erytech — ERYtech Pharma, set up in Lyon (France) in 2004, specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.
  • Sportsrocket — Sportsrocket is a New York-based company working to give sports fans access to live games and events, highlights, and shows. The company works with leading leagues, publishers, and rights-holders, including Major League Soccer, the PGA Tour, Scout Media, and AS Roma, to create and power customized OTT platforms. Incubated by Bedrocket Media Ventures, Sportsrocket's innovative approach is based on a proprietary sports media operating system, that offers an integrated solution for the production, distribution, management, and monetization of sports media across all platforms.
Show all investments...

Aravis Ventures
VC Fund · Zurich, Zurich, Switzerland · 4 investments in Switzerland Biotech startups

Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30 leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: Switzerland, United States, Belgium

Investor stats

  • Total investments: 19
  • Round size: Series A $4.4M–$80M; Series B $7M–$33M
  • Lead/follow: 32% lead, 68% follow

Portfolio highlights

  • Bird Rock Bio — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
  • Synaffix BV — Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
  • Hedera-22 — Explore the top online casino no verification withdrawal Australia sites. Fast payouts, crypto banking, and safe pokies at trusted no KYC casinos.
Show all investments...

b2venture
VC Fund · Saint Gallen, Sankt Gallen, Switzerland · 4 investments in Switzerland Biotech startups, 8 in the past 12 months

b2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.

Show more...

Investment focus

  • Industry: Software, Health Care, Information Technology
  • Stage:Series A, Seed, Series B
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 285
  • Round size: Seed $1.3M–$8.8M; Series A $3.4M–$23M; Series B $6.9M–$52M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: Likely actively investing — fresh fund, raised $179M in 2026

Portfolio highlights

  • 1Komma5° — 1KOMMA5° is a global decarbonisation energy company focusing on intelligent energy solutions and promoting a CO2-neutral lifestyle. They are a ClimateTech startup focused on CO2-neutral energy, heating, and mobility. The company functions at approximately 80 sites across 7 global markets, providing a comprehensive range of smart, integrated energysolutions including photovoltaics, energy storage, heat pumps, and electric vehicle charging stations.
  • Flyboard — Human-level AI voice agents at a fraction of the cost. Transform your customer engagement with intelligent automation.
  • Procuros — More and more sales teams struggle with supplier portals. We help you integrate digitally with common supplier portals and consolidate all order documents.
Show all investments...

EVA Basel
VC Fund · Basel, Basel-Stadt, Switzerland · 4 investments in Switzerland Biotech startups

EVA is sparring partner for new entrepreneurs in the Life Sciences with planned base in north-western SwitzerlandThey support start-ups by helping to bridge the gap between their business idea and the successful commercialization of their life sciences projects, innovations and technologies.They provide thorough coaching and activelyencourage contact with their wide-ranging network of experts and investors as well as providing seed-phase investments.In science and technology transfer, they act as the link between researchers, universities’ scientific liaison offices, potential investors and the market.

Show more...

Investment focus

  • Industry: Biotechnology, Medical Device, Pharmaceutical
  • Stage:Seed, Series A
  • Geography: Switzerland

Investor stats

  • Total investments: 5
  • Round size: Seed $1.9M–$3.7M
  • Lead/follow: 40% lead, 60% follow

Portfolio highlights

  • POLYNEURON — Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner.
  • Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
  • Inthera Bioscience — Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.
Show all investments...

Polytech Ventures
VC Fund · Lausanne, Vaud, Switzerland · 4 investments in Switzerland Biotech startups

Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world

Show more...

Investment focus

  • Industry: Software, Financial Services, FinTech
  • Stage:Seed, Series A, Venture - Series Unknown
  • Geography: Switzerland, United States, Spain

Investor stats

  • Total investments: 53
  • Round size: Seed $500k–$3.5M; Series A $2.1M–$10M; Venture - Series Unknown $1.3M–$5.4M
  • Lead/follow: 26% lead, 74% follow
  • Last fund: May invest from a new fund soon — raised $40M in 2016

Portfolio highlights

  • Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
  • Hemostod — Developing universal platelets and next-generation diagnostics
  • Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Show all investments...

ETH Zurich Foundation
VC Fund · Zürich, Zurich, Switzerland · 3 investments in Switzerland Biotech startups

ETH Zurich Foundation is an independent, non-​profit-making foundation under private law for the promotion of education and research at ETH Zurich.

Show more...

Investment focus

  • Industry: Medical, Software, 3D Printing
  • Stage:Pre-Seed, Seed, Grant
  • Geography: Switzerland

Investor stats

  • Total investments: 22
  • Round size: Seed $1.1M–$5.6M; Grant $152k–$175k; Pre-Seed $473k–$4.4M
  • Lead/follow: 9% lead, 91% follow

Portfolio highlights

  • Soverli — Soverli is a cybersecurity technology firm that provides advanced protection technologies for smartphones.
  • Immitra Bio — Developing scalable in-vivo genomic medicine for blood disorders
  • Tethys Robotics — Tethys Robotics develops AI-powered application oriented robotics system that enables professionals in carrying underwater search & recovery to inspection & surveillance.
Show all investments...

BB Biotech Ventures
VC Fund · Zürich, Zurich, Switzerland · 3 investments in Switzerland Biotech startups

BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernsey—based fund is advised by the Bellevue Asset Management Group, which has operations in Curaçao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated team of investment advisors and an advisory board. In addition, it is supported by all of the Group’s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series C, Series A, Series B
  • Geography: United States, Switzerland, Italy

Investor stats

  • Total investments: 38
  • Round size: Series A $1.4M–$24M; Series B $9M–$132M; Series C $11M–$66M
  • Lead/follow: 11% lead, 89% follow
  • Last fund: May invest from a new fund soon — raised $96M in 2009

Portfolio highlights

  • Arvinas — Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
  • Molecular Templates — Molecular Templates is a clinical-stage biopharmaceutical company developing engineered toxin bodies (ETBs) for the treatment of cancers.
  • Rivus Pharmaceuticals — Rivus Pharmaceuticals, a leader in mitochondrial biology, is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity.
Show all investments...

Bpifrance
VC Fund · Maisons-alfort, Ile-de-France, France · 3 investments in Switzerland Biotech startups

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Venture - Series Unknown, Series A
  • Geography: France, United States, Switzerland

Investor stats

  • Total investments: 1745
  • Round size: Seed $752k–$6.1M; Series A $2.6M–$34M; Venture - Series Unknown $1.1M–$32M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: Likely actively investing — fresh fund, raised $27M in 2025

Portfolio highlights

  • Proteor — Proteor offers a complete range of high quality products and services to the O&P world, through more than 60 clinics.
  • Advicenne — Specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and neurology.
  • BiPER Therapeutics — BiPER Therapeutics is a biotech company to develop and commercializes novel therapeutics.
Show all investments...

Joyance Partners
VC Fund · San Francisco, California, United States · 3 investments in Switzerland Biotech startups

Joyance Partners invests in companies that, through science and tech, cultivate joy to improve how we live, focusing on the health and consumer sectors from Pre-Seed to Series A.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Wellness
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United States, Germany, United Kingdom

Investor stats

  • Total investments: 122
  • Round size: Seed $960k–$6M; Pre-Seed $500k–$2M; Series A $3.6M–$18M
  • Lead/follow: 7% lead, 93% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Siena AI — The autonomous customer service platform designed for commerce. Combine the best of human empathy and intelligent automation to transform the way your customer service teams operate and engage with shoppers.
  • KilgourMD — Dermatologist-developed, the best hair growth products for thinning hair. Reduce hair fall by 30% in two months, and stimulate hair follicle growth by 200%. No known side effects.
  • Nous — Find out exactly how your household finances will be affected by the cost-of-living crisis with Nous on your side.
Show all investments...

Biotech VC funding in Switzerland at a glance

Stats across 1.3k deals from 833 investors.

833
investors
in Switzerland Biotech startups
1.3k
deals
in Switzerland Biotech startups
$1.4M
median round
in Switzerland Biotech startups
50%
lead investors
lead at least one round
33%
Grant
most common funding stage

Access all 833 VC funds in Switzerland Biotech startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotech VC Funds in Switzerland investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 833 VC funds investing in Switzerland Biotech startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists

Broader lists